A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia

Journal of Psychopharmacology

Volumn 30, Issue 1, 2016, Pages 69-77

  Tandon, Rajiv ^a   Cucchiaro, Josephine ^b   Phillips, Debra ^b   Hernandez, David ^b   Mao, Yongcai ^b   Pikalov, Andrei ^b   Loebel, Antony ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

antipsychotic agents; drug therapy; Lurasidone; maintenance treatment; relapse prevention; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; HYPNOTIC SEDATIVE AGENT; LIPID; LURASIDONE; PLACEBO; PROLACTIN; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ANXIETY; ARTICLE; BACKACHE; BEHAVIOR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FRANCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; ITALY; KAPLAN MEIER METHOD; LIPID BLOOD LEVEL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROBABILITY; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; RISK REDUCTION; RUSSIAN FEDERATION; SCHIZOPHRENIA; SEDATION; SERBIA; SIDE EFFECT; SLOVAKIA; SOMNOLENCE; SOUTH AFRICA; SUICIDAL IDEATION; TOOTH PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; CLINICAL TRIAL; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; TIME FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LURASIDONE HYDROCHLORIDE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84952037843     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881115620460     Document Type: Article

References (38)

1. Agid O, Siu CO, Potkin SG, et al. (2013) Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 170: 1335-1344.
2. Arato M, O'Connor R, Meltzer HY, (2002) A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17: 207-215.
3. Barnes TR, (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Beasley CM Jr, Sutton VK, Hamilton SH, et al. (2003) A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23: 582-594.
5. Chen YF, Wang SJ, Khin NA, et al. (2010) Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 9: 217-229.
6. Citrome L, (2011) Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 65: 189-210.
7. Citrome L, (2012) Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses 6: 76-85.
8. Citrome L, Cucchiaro J, Sarma K, et al. (2012) Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 27: 165-176.
9. Citrome L, Weiden PJ, McEvoy JP, et al. (2014) Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 19: 330-339.
10. Committee for Medicinal Products for Human Use (CHMP) (2012) Guideline on Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia. London: European Medicines Agency.
11. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16-22.
12. Department Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research (2005) PDAC transcript. Gaithersburg, MD: Food and Drug Administration. Available at: http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4186T1.pdf (. accessed 8 October 2015).
13. Emsley R, Chiliza B, Asmal L, (2013) The evidence for illness progression after relapse in schizophrenia. Schizophr Res 148: 117-121.
14. Guy W,. (1976) ECDEU Assessment Manual for Psychopharmacology Revised. Publication ADM 76-338. Rockville, MD: National Institute of Mental Health.
15. 1A receptor activity. J Pharmacol Exp Ther 334: 171-181.
16. Kane JM, (2007) Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry 68: 27-30.
17. Kane JM, Mackle M, Snow-Adami L, et al. (2011) A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 72: 349-355.
18. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
19. Kemp AS, Schooler NR, Kalali AH, et al. (2010) What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36: 504-509.
20. Khin NA, Chen YF, Yang Y, et al. (2012) Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 73: 856-864.
21. Kramer M, Simpson G, Maciulis V, et al. (2007) Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27: 6-14.
22. Leucht S, Cipriani A, Spineli L, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382: 951-962.
23. Leucht S, Tardy M, Komossa K, et al. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379: 2063-2071.
24. Loebel A, Cucchiaro J, Sarma K, et al. (2013a) Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 145: 101-109.
25. Loebel A, Cucchiaro J, Xu J, et al. (2013b) Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophr Res 147: 95-102.
26. Meltzer HY, Cucchiaro J, Silva R, et al. (2011) Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 168: 957-967.
27. Nakamura M, Ogasa M, Guarino J, et al. (2009) Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 70: 829-836.
28. Nasrallah HA, Silva R, Phillips D, et al. (2013) Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 47: 670-677.
29. Ogasa M, Kimura T, Nakamura M, et al. (2013) Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 225: 519-530.
30. Peuskens J, Trivedi J, Malyarov S, et al. (2007) Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont) 4: 34-50.
31. Pigott TA, Carson WH, Saha AR, et al. (2003) Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64: 1048-1056.
32. Posner K, Brown GK, Stanley B, et al. (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266-1277.
33. Rutherford BR, Pott E, Tandler JM, et al. (2014) Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 71: 1409-1421.
34. Simpson GM, Angus JW, (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
35. Stahl SM, Cucchiaro J, Simonelli D, et al. (2013) Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry 74: 507-515.
36. ® (lurasidone HCI) Tablets. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/200603s001lbl.pdf (. accessed 8 October 2015).
37. Tandon R, Nasrallah HA, Keshavan MS, (2009) Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 110: 1-23.
38. Tandon R, Nasrallah HA, Keshavan MS, (2010) Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res 122: 1-23.